Home » Stocks » TXMD

TherapeuticsMD, Inc. (TXMD)

Stock Price: $1.14 USD -0.05 (-4.22%)
Updated Apr 19, 2021 11:26 AM EDT - Market open
Market Cap 465.93M
Revenue (ttm) 64.87M
Net Income (ttm) -183.52M
Shares Out 275.65M
EPS (ttm) -0.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $1.14
Previous Close $1.19
Change ($) -0.05
Change (%) -4.22%
Day's Open 1.17
Day's Range 1.12 - 1.19
Day's Volume 3,647,191
52-Week Range 0.90 - 2.75

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

TherapeuticsMD (TXMD) stock is up on Friday after announcing approval for one of its hormone treatments in two parts of Europe. The post TXMD Stock: The News Giving TherapeuticsMD Shares a Shot in the A...

1 week ago - InvestorPlace

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women's healthcare company, and Theramex, a dedicated women's health company, announced that BIJUVE® has re...

1 week ago - Business Wire

Retail investors over on Reddit Penny Stocks are showing interest in quite a few interesting players today that investors will want to note. The post 7 Reddit Penny Stocks Seeing the Most Chatter Today ...

Other stocks mentioned: ATNF, CTXR, MARA, SNDL, SVRA, ZOM
1 month ago - InvestorPlace

LONDON--(BUSINESS WIRE)--Theramex, a global company specialised in women's health, announced today the Decentralised Procedure approval in several EU countries and the UK of BIJUVA® (1 mg estradiol / 10...

1 month ago - Business Wire

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -50.00% and 6.12%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Shares of TherapeuticsMD (NASDAQ:TXMD) rose 9.3% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 21.05% over the past year to ($0.15), which missed...

1 month ago - Benzinga

BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD net product revenue in 2020 increased 84% over 2019; conference call at 8:30am ET today to discuss financial and business results for 2020.

1 month ago - Business Wire

BOCA RATON, Fla.--(BUSINESS WIRE)--March Conferences

1 month ago - Business Wire

TherapeuticsMD (TXMD) closed the most recent trading day at $1.63, moving +1.24% from the previous trading session.

1 month ago - Zacks Investment Research

BOCA RATON, Fla.--(BUSINESS WIRE)--4Q date announcement press release

1 month ago - Business Wire

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the closing of its underwritten public offering of 59,459,460 shares of its common stock for net proceeds of approxi...

2 months ago - Business Wire

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the pricing of its underwritten public offering of approximately 59.5 million shares of its common stock for gross p...

2 months ago - Business Wire

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced an underwritten public offering of its common stock. The Company has granted the underwriter a 30-day option to purc...

2 months ago - Business Wire

Pessimists have piled into these companies, but that doesn't seem to be fazing millennial investors one bit.

Other stocks mentioned: AMC, GME, INO, AAL, BLNK, NKLA, SPCE ...
2 months ago - The Motley Fool

The movement of retail traders against hedge funds has caused several stocks to spike. Many of the top movers have been stocks that have a high percentage of their floated shares short, causing what's k...

Other stocks mentioned: CLVS, DVAX, LCI, NAKD, OPK, PGEN, SENS ...
2 months ago - Benzinga

Now that AMC, GameStop, American Airlines and Bed, Bath & Beyond have been pushed to wild levels, well above any sane valuation, the question is which companies will be the next to be “recommended” by m...

Other stocks mentioned: CPRX
2 months ago - 24/7 Wall Street

TherapeuticsMD (TXMD) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

3 months ago - Zacks Investment Research

BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD to present at H.C. Wainwright BioConnect Conference and J.P. Morgan Virtual HealthCare Conference in January 2021

3 months ago - Business Wire

BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD closes offering; sold 23,437,500 shares of its common stock for net proceeds of approximately $27.5 million

5 months ago - Business Wire

BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD to present at Stifel 2020 Virtual Healthcare Conference on Tuesday, Nov. 17 at 9:20 a.m. ET; see details for live webcast

5 months ago - Business Wire

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the pricing of its underwritten public offering of approximately 23.4 million shares of its common stock for gross p...

5 months ago - Business Wire

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced an underwritten public offering of its common stock. The Company has granted the underwriter a 30-day option to purc...

5 months ago - Business Wire

TherapeuticsMD's (TXMD) CEO Robert Finizio on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of 28.57% and 9.47%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Shares of TherapeuticsMD (NASDAQ:TXMD) moved higher by 2.5% in pre-market trading after the company reported Q3 results.

5 months ago - Benzinga

BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD releases Q3 business and financial results; holds conference call at 8:30 am ET today

5 months ago - Business Wire

TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD to hold conference call to discuss Q3 financial and business results on Monday, November 9 at 8:30 am ET

5 months ago - Business Wire

TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Give TXMD stock a try if you're ready to expand your portfolio's horizons with a stake in innovative women's health care products. The post Delve into an Underappreciated Health Care Niche with Therapeu...

5 months ago - InvestorPlace

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women’s healthcare company, is proud to reinforce the importance of empowering women to make informed choices about t...

6 months ago - Business Wire

Investors need to pay close attention to TherapeuticsMD (TXMD) stock based on the movements in the options market lately.

6 months ago - Zacks Investment Research

BOCA RATON, Fla.--(BUSINESS WIRE)--3Q Update PR

6 months ago - Business Wire

MONTREAL and BOCA RATON, Fla., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”) announced today the approval...

Other stocks mentioned: KHTRF
6 months ago - GlobeNewsWire

BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD to participate in two virtual investor conferences in September

7 months ago - Business Wire

BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD increases patent protection on ANNOVERA

7 months ago - Business Wire

TherapeuticsMD has been a blemish on my speculative biotech/pharma portfolio for over a year. I went against my rules for trading a premium-priced bio and paid for it.

7 months ago - Seeking Alpha

MONTREAL and BOCA RATON, Fla, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”) announced today the approval o...

7 months ago - GlobeNewsWire

TherapeuticsMD, Inc. (TXMD) CEO Robert Finizio on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -13.33% and -10.30%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD discusses business and financial results for Q2 2020 on earnings conference call today at 8:30 a.m.

8 months ago - Business Wire

TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc.

8 months ago - Business Wire

TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

BOCA RATON, Fla. & SAN FRANCISCO--(BUSINESS WIRE)--TXMD expands access to Annovera through arrangement with Nurx, the largest online practice for women's health

9 months ago - Business Wire

Being concerned about the elevated levels of the market is likely to be on many investors’ minds ahead of a slew of corporate earnings coming, not to mention an election season that is only going to get...

Other stocks mentioned: AIRG, BHF, SLNO, VECO
9 months ago - Forbes

Have extra cash to spare? These drug stocks are significantly undervalued and could make you wealthy in the long run.

Other stocks mentioned: ENDP, MYL
10 months ago - The Motley Fool

TherapeuticsMD, Inc. (TXMD) CEO Robert Finizio on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -10.53% and 6.72%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

A newly issued patent could provide market exclusivity for its long-term contraceptive device.

11 months ago - The Motley Fool

About TXMD

TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; and TX-007HR and TX-... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
CEO
Robert Finizio
Employees
400
Stock Exchange
NASDAQ
Ticker Symbol
TXMD
Full Company Profile

Financial Performance

In 2020, TherapeuticsMD's revenue was $64.87 million, an increase of 30.67% compared to the previous year's $49.65 million. Losses were -$183.52 million, 4.19% more than in 2019.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for TherapeuticsMD stock is "Strong Buy." The 12-month stock price forecast is 6.17, which is an increase of 443.61% from the latest price.

Price Target
$6.17
(443.61% upside)
Analyst Consensus: Strong Buy